However, a few previous studies have reported promising efficacies of anti-EGFR monoclonal antibodies (such as cetuximab and nimotuzumab) plus chemoradiotherapy in advanced ESCC patients using single-arm trials, with an ORR of 51.8%–100%11,14–17, which indicated the benefits of combination therapy. Here, EGFR is linked to esophageal squamous cell carcinoma.